COMPANY PROFILE

EBAMed

Explore full profile

Developing innovative solutions for non-invasive and automated treatment of heart arrhythmias by using protontherapy

Geneva, SwitzerlandFounded 2018Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2025

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About EBAMed

Developer of diagnostic equipment designed for non-invasive and automated treatment of heart arrhythmias. The company's device utilizes a proton therapy capable of selectively treating the tissues responsible for arrhythmias of the heart, enabling patients to gain a non-invasive way of treatment, in a single out-patient session. Keywords: Healthcare Devices, Services, Supplies, Arrhythmias Treatment, Automated Heart Treatment, Catheter Procedures, Heart Arrhythmias Treatment, Heart Treatment Device, Medical Device Firm, Noninvasive Treatment.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Geneva, Switzerland
Employees: 18
Open positions: None listed
Dealroom signal: 82.4/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Non-Invasive medical devices and treatments, EIC, Biotech and Pharma, EIC Fund, Horizon Europe
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning EBAMed.

See all news

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jan 2025	$1.8M	$79M	CDP Venture Capital	↗
SERIES A✓Equity / VC	Jun 2023	$16M	$63M	Mayo Clinic · EFI Lake Geneva Ventures · EIC Fund · OCCIDENT	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

EBAMed website traffic

Latest recorded traffic for EBAMed is 1.3K monthly website visits, up 18.2% over the last three months. EBAMed's team grew 20% over the past year.

Latest monthly visits1.3K 3-month web change+18.2% 1-year team growth+20%

Monthly website visitsJun 2018–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CRCroivalveTreating Heart Valve Disease	Dublin, Ireland	Operational	61	$63M	$80M
AMArtiria MedicalProvides micro-actuated device allowing to treat vascular diseases	Borex, Switzerland	Operational
KRKribaNon-invasive screening and monitoring of serous fluids infections of the body	Madrid, Spain	Operational
FEFeopsCutting-edge technology that creates digital twins from cardiac scans	Ghent, Belgium	Acquired
CTCoramaze TechnologiesDevelops valve repair systems to tackle cardiovascular diseases	Hilden, Germany	Operational
NANanoPhoriaNon-viral nanoparticle drug delivery platform for cardiovascular treatments	Milan, Italy	Operational
SESentanteDeveloping a radiation-reducing manipulator and a minimally invasive coronary robotic system for endovascular procedures	Kaunas, Lithuania	Operational
LVLUMA VisionWe enable Cardiologists to save lives through exceptional decision-making accuracy	Dublin, Ireland	Operational